Autologous hematopoietic stem cell transplantation following XXXX for non- @entity980 soft @entity242 .

@entity1 @entity137 @entity242 @entity5 @entity1503 @entity2101 @entity980 @entity1349
BACKGROUND: Soft @entity242 (STS) are a highly heterogeneous group of rare malignant solid @entity5 . Non- @entity980 soft @entity242 (NRSTS) comprise all STS except @entity980 . In @entity1 with advanced local or metastatic disease, autologous hematopoietic stem cell transplantation (HSCT) applied after @entity2101 ( @entity2101 ) is a planned rescue therapy for @entity2101 -related severe @entity1503 . OBJECTIVES: To assess the effectiveness and safety of @entity2101 followed by autologous HSCT for all stages of soft @entity242 in @entity1 and adults. SEARCH STRATEGY: We searched the electronic databases CENTRAL (The Cochrane Library 2010, Issue 2), MEDLINE and EMBASE (February 2010). Online trial registers, congress abstracts and reference lists of reviews were searched and expert panels and authors were contacted. SELECTION CRITERIA: Terms representing STS and autologous HSCT were required in the title, abstract or keywords. In studies with aggregated data, @entity1 with NRSTS and autologous HSCT had to constitute at least 80% of the data. Comparative non-randomized studies were included because randomized controlled trials (RCTs) were not expected. Case series and case reports were considered for an additional descriptive analysis. DATA COLLECTION AND ANALYSIS: Study data were recorded by two review authors independently. For studies with no comparator group, we synthesised results for studies reporting aggregate data and conducted a pooled analysis of individual @entity1 data using the Kaplan-Meyer method. The primary outcomes were @entity1349 ( @entity1349 ) and treatment-related mortality (TRM). MAIN RESULTS: We included 54 studies, from 467 full texts articles screened (11.5%), reporting on 177 @entity1 that received HSCT and 69 @entity1 that received standard care. Only one study reported comparative data. In the one comparative study, @entity1349 at two years after HSCT was estimated as statistically significantly higher (62.3%) compared with @entity1 that received standard care (23.2%). In a single-arm study, the @entity1349 two years after HSCT was reported as 20%. In a pooled analysis of the individual data of 54 @entity1 , @entity1349 at two years was estimated as 49% (95% CI 34% to 64%). Data on TRM, secondary @entity5 and severe @entity137 grade 3 to 4 after transplantation were sparse. All 54 studies had a high risk of bias. AUTHORS' CONCLUSIONS: Due to a lack of comparative studies, it is unclear whether @entity1 with NRSTS have improved survival from autologous HSCT following @entity2101 . Owing to this current gap in knowledge, at present @entity2101 and autologous HSCT for NRSTS should only be used within controlled trials.
